It has been reported that the time interval between consecutive HER2–targeted therapies in BC may play a key role in cross–resistance, as HER2 downregulation is associated with a shorter interval between the last HER2–targeted agent administered and the time of HER2 assessment (45). The gene discussed is ERBB2; the disease is breast cancer.